公开(公告)号：US11785841B2

公开(公告)日：2023-10-10

申请号：US16732136

申请日：2019-12-31

申请人： WUHAN TIANMA MICROELECTRONICS CO., LTD. ,  WUHAN TIANMA MICROELECTRONICS CO., LTD. SHANGHAI BRANCH

发明人： Wenpeng Dai ,  Wei Gao ,  Jinghua Niu ,  Lei Zhang ,  Yang Li ,  Dongyang Deng ,  Ping An

IPC分类号： H10K85/60 ,  C07D401/10 ,  C07D403/08 ,  C07D403/14 ,  C09K11/06 ,  H10K50/11 ,  H10K50/15 ,  H10K50/16 ,  H10K101/10 ,  H10K101/30

CPC分类号： H10K85/615 ,  C07D401/10 ,  C07D403/08 ,  C07D403/14 ,  C09K11/06 ,  H10K85/622 ,  H10K85/654 ,  H10K85/6572 ,  C09K2211/1018 ,  H10K50/11 ,  H10K50/15 ,  H10K50/16 ,  H10K2101/10 ,  H10K2101/30

摘要： A compound having a D-(π)-σ-(π)-A chemical structure and improving brightness and efficiency of light-emitting is described. In an embodiment, the compound has a chemical structure according to Formula (I), in which L1 and L2 are each at least one of a single bond, C1-C20 alkylene, C3-C20 cycloalkylene, C3-C20 heterocyclic alkylene, C6-C40 arylene, C4-C40 heteroarylene, C10-C60 fused arylene, or C10-C60 fused heteroarylene; the electron donor D is C1-C20 alkyl, C3-C20 cycloalkyl, C1-C20 alkoxy, C3-C20 heterocyclic group, C6-C40 aryl, C4-C40 heteroaryl, C10-C60 fused arylene, C10-C60 fused heteroarylene, C12-C40 carbazolyl and its derivative groups, C12-C40 diphenylamino and its derivative groups, C18-C60 triphenylamino and its derivative groups, or C12-C40 acridinyl and its derivative groups; and the electron acceptor A is a nitrogen-containing heterocyclic group, a cyano-containing group, a triarylboron-based group, a benzophenone-based group, an aromatic heterocyclic ketone-based group, a sulfone-based group, or a phosphoroso-containing groups.

公开(公告)号：US11753381B2

公开(公告)日：2023-09-12

申请号：US17033104

申请日：2020-09-25

申请人： Board of Regents, The University of Texas System

发明人： Richard T. Lewis ,  Matthew Michael Hamilton ,  William J. Ray ,  Fernando Alvarez ,  Dana E. Pfaffinger ,  Naphtali Reyna ,  Jason Cross ,  Suyambu Kesava Vijayan Ramaswamy

IPC分类号： C07D231/06 ,  A61K31/4965 ,  A61K31/415 ,  A61K31/416 ,  C07D231/56 ,  C07D403/12 ,  A61K31/506 ,  A61K31/5377 ,  C07D401/14 ,  A61K31/4439 ,  C07D471/04 ,  A61K31/437 ,  C07D403/08 ,  A61K31/4155 ,  C07D413/08 ,  A61K31/4245 ,  A61K31/4184 ,  C07D207/10 ,  A61K31/40 ,  A61K31/4015 ,  C07D401/12 ,  C07D403/14 ,  A61K31/497 ,  A61K31/4192 ,  C07D487/04 ,  A61K31/4985 ,  C07D417/14 ,  A61K31/427 ,  C07D241/24 ,  A61K45/06

CPC分类号： C07D231/06 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4155 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/427 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/4965 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D207/10 ,  C07D231/56 ,  C07D241/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/08 ,  C07D403/12 ,  C07D403/14 ,  C07D413/08 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

公开(公告)号：US20230167089A1

公开(公告)日：2023-06-01

申请号：US17944851

申请日：2022-09-14

申请人： Ningbo Lumilan Advanced Materials Co., Ltd.

发明人： Xiangzhi LI ,  Ye CAI ,  Ting-Wei WEI ,  Zhi-Kuan CHEN

IPC分类号： C07D403/08 ,  C07D405/14 ,  C07D403/14 ,  C07D409/14 ,  C07C211/54 ,  C07D307/91 ,  C07D405/12 ,  H01L51/00

CPC分类号： C07D403/08 ,  C07C211/54 ,  C07D307/91 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  H01L51/0067

摘要： The present invention provides an organic material composition and applications thereof. By the combination of the compounds comprised in the organic material composition, the organic material composition makes the element have a lower driving voltage, a higher current efficiency and a longer service life.

公开(公告)号：USRE49338E1

公开(公告)日：2022-12-20

申请号：US16447174

申请日：2019-06-20

申请人： IDIENCE CO., LTD

发明人： Jae-Hoon Kang ,  Hong-Sub Lee ,  Yoon-Suk Lee ,  Joon-Tae Park ,  Kyung-Mi An ,  Jin-Ah Jeong ,  Kyung-Sun Kim ,  Jeong-Geun Kim ,  Chang-Hee Hong ,  Sun-Young Park ,  Dong-Keun Song ,  Yong-Don Yun

IPC分类号： C07D417/14 ,  C07D403/08 ,  C07D401/14 ,  C07D403/14 ,  C07D403/10

摘要： The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

公开(公告)号：US11422403B2

公开(公告)日：2022-08-23

申请号：US16767056

申请日：2018-11-27

申请人： NITTO DENKO CORPORATION

发明人： Michael Welch ,  Shijun Zheng ,  Peng Wang

IPC分类号： C09B57/00 ,  G02B5/22 ,  G02F1/1335 ,  C07D403/08 ,  H01L33/50 ,  G02F1/13363 ,  C07D207/44 ,  C07D209/60 ,  C07D207/00 ,  C07D209/00 ,  C07D403/00 ,  C09J7/38 ,  C09J7/10 ,  C09J11/06 ,  C09J7/20 ,  G02F1/1333 ,  G02B1/10

摘要： Described herein are embodiments of squarylium compounds for use as filters in light-emitting and/or display devices. One problem of known quarylium dyes is that strong nucleophiles can attack the electron-deficient cyclobutene ring which can lead to a loss of the dye's colour. Another potential drawback with squaraine dyes can be their tendency to form aggregates, which can lead to a substantial broadening of their absorption bands. Use of the present compounds in filters address these problems. The squarylium compounds of the present invention have the following formulas:

公开(公告)号：US20220202726A1

公开(公告)日：2022-06-30

申请号：US17696984

申请日：2022-03-17

申请人： VICORE PHARMA AB

发明人： Ola CAMBER ,  Arnout EVERAERT ,  Stefan GRUDÉN

IPC分类号： A61K9/48 ,  C07D403/08 ,  A61K9/00

摘要： There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and/or a volume-based mean diameter, and/or a structural/particle density, that is/are similar to the weight- and/or volume-based mean diameter, and/or the structural/particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and/or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

公开(公告)号：US20220178921A1

公开(公告)日：2022-06-09

申请号：US17454300

申请日：2021-11-10

申请人： VisEn Medical, Inc.

发明人： Narasimhachari Narayanan

IPC分类号： G01N33/569 ,  C09B23/01 ,  C09B23/08 ,  G01N33/58 ,  A61K49/00 ,  A61K51/04 ,  C07D403/08 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14

摘要： The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications.

公开(公告)号：US11352367B2

公开(公告)日：2022-06-07

申请号：US17045675

申请日：2019-04-05

申请人： TARO PHARMACEUTICALS INC.

发明人： Curtis Harwig ,  Jeremy D. Pettigrew ,  Jennifer Cross ,  Jeyaprakashnarayanan Seenisamy ,  Mahesh Narayan Keregadde ,  Karthikeyan Iyanar

IPC分类号： C07D493/10 ,  C07D231/54 ,  C07D401/08 ,  C07D403/08 ,  C07D417/08 ,  A61P29/00

摘要： Compounds of formula (I): wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.

公开(公告)号：US11332463B2

公开(公告)日：2022-05-17

申请号：US17049653

申请日：2019-04-29

申请人： Merck Sharp & Dohme Corp.

发明人： Brendan M. Crowley ,  Brian T. Campbell ,  Harry R. Chobanian ,  James I. Fells ,  Deodial G. Guiadeen ,  Thomas J. Greshock ,  Kenneth J. Leavitt ,  Vanessa L. Rada ,  Ian M. Bell

IPC分类号： C07D413/08 ,  C07D413/14 ,  C07D417/08 ,  C07D417/14 ,  C07D403/08 ,  C07D513/04 ,  C07D471/04 ,  C07D487/04 ,  A61P25/00

摘要： The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).

公开(公告)号：US20220106321A1

公开(公告)日：2022-04-07

申请号：US17538532

申请日：2021-11-30

申请人： Katholieke Universiteit Leuven

发明人： Dorothée Bardiot ,  Gunter Carlens ,  Kai Dallmeier ,  Suzanne Kaptein ,  Michael McNaughton ,  Arnaud Marchand ,  Johan Neyts ,  Wim Smets ,  Mohamed Koukni

IPC分类号： C07D487/04 ,  C07D401/12 ,  C07D413/12 ,  C07D209/14 ,  C07D409/08 ,  C07D498/04 ,  C07D403/08 ,  C07D471/04 ,  C07D495/04 ,  C07D413/08 ,  C07D405/12 ,  C07D403/12 ,  C07D403/10 ,  C07D513/04 ,  C07D401/08 ,  C07D417/14 ,  C07D409/12 ,  C07D401/14 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D413/06

摘要： The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.